The company's ADCs use a careful selection of payload, linker, and conjugation chemistry to target haematological and solid tumours, with a focus on non-prodrug/prodrug DNA and protein alkylating payloads. Their proprietary PermaLink® platform provides stable conjugation chemistries, which significantly improves the therapeutic index of this modality, ultimately improving patient outcomes.